Fiche publication
Date publication
septembre 2020
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
Tous les auteurs :
Albiges L, Barthélémy P, Gross-Goupil M, Negrier S, Needle MN, Escudier B
Lien Pubmed
Résumé
Treatment with tivozanib, a highly selective and potent vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), has demonstrated single-agent efficacy in advanced renal cell carcinoma (RCC) along with minimal off-target toxicities and a favorable adverse event (AE) profile. We report final results from TiNivo, a phase Ib/II study of tivozanib combined with nivolumab.
Mots clés
PD-1, Renal cell carcinoma, VEGFR TKI, nivolumab, tivozanib
